Areteia Therapeutics
Areteia Therapeutics was a clinical-stage biopharmaceutical company (founded 2022) that developed dexpramipexole, an oral small-molecule candidate for eosinophilic asthma, before ceasing operations prior to commercialization.
- Company typePrivate
- Founded2022
- HeadquartersBernardsville, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Areteia Therapeutics does
Areteia Therapeutics was a clinical-stage biopharmaceutical company founded in July 2022 by Knopp Biosciences and Population Health Partners as a dedicated vehicle to develop dexpramipexole, an oral small-molecule drug candidate designed to lower eosinophil levels in patients with eosinophilic asthma. The company's central thesis was to provide a convenient oral alternative to injectable biologic therapies and chronic corticosteroid use for the eosinophilic asthma subpopulation, with the active ingredient in-licensed/derived from founding asset contributor Knopp Biosciences. Areteia operated as a single-asset, clinical-stage biotech and dosed the first patients in its global Phase III program in March 2023, evaluating dexpramipexole on the primary endpoints of asthma exacerbation reduction and lung-function improvement.
The company was funded exclusively through Series A capital: an initial $350 million tranche led by Bain Capital Life Sciences with participation from Sanofi and a broader investor syndicate in July 2022, followed by a $75 million top-up in February 2024 (also led by Bain Capital Life Sciences with Sanofi re-participating), bringing total Series A funding to $425 million. The February 2024 capital was earmarked for expansion of Phase III development to Japan and other markets, manufacturing, formulation development, and global commercial preparation. Areteia assembled a full clinical-stage management team across medical, development, scientific, commercial, legal, and finance functions, with co-founder Jorge Bartolome as CEO and co-founder Christopher Courts as CFO.
Areteia was a pre-commercial, pre-revenue entity with no approved product and no disclosed pricing model. The company's website now states that it 'is no longer operating,' with correspondence redirected through a Foxboro, MA mailing address and asset inquiries routed to a financial-advisory intermediary (Rock Creek Financial Advisors), indicating a wind-down or asset-disposition restructuring. No acquisition, merger, or licensing outcome for the dexpramipexole program is disclosed in the available data.
Areteia Therapeutics firmographics
Firmographics- Name
- Areteia Therapeutics
- Legal name
- Areteia Therapeutics, Inc.
- Website
- https://areteiatx.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Closed
- Headcount range
- 11–50 employees
- Short description
- Areteia Therapeutics was a clinical-stage biopharmaceutical company (founded 2022) that developed dexpramipexole, an oral small-molecule candidate for eosinophilic asthma, before ceasing operations prior to commercialization.
- Ownership category
- akta.pro rank
Areteia Therapeutics industry classification
Industry- Product category
- Respiratory Therapeutics
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Respiratory & Allergy Pharmaceuticals (HLAIAAAH)
Keywords
Where Areteia Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Bernardsville
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Areteia Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Others
Areteia Therapeutics product offering
Product offeringCore offering
Areteia Therapeutics is developing dexpramipexole, an oral drug candidate designed to lower eosinophil levels in patients with eosinophilic asthma. The lead asset is intended as an oral alternative to injectable biologic therapies and corticosteroids, with the goal of reducing asthma exacerbations and improving lung function. The company was advancing dexpramipexole through Phase III clinical trials as a single-asset clinical-stage biopharmaceutical program.
Product overview
Areteia Therapeutics was a clinical-stage biopharmaceutical company focused on developing dexpramipexole as an oral treatment for eosinophilic asthma. The company operated as a single-product entity with its lead candidate progressing through Phase III clinical trials. The company is no longer operating.
Differentiator
Problem solved
Functional benefit
Products and services
- Dexpramipexole An oral drug candidate designed to lower eosinophil levels in patients with eosinophilic asthma, intended as a non-injectable, non-steroidal alternative to biologic therapies and chronic corticosteroids; for patients, prescribers, and payers managing severe eosinophilic asthma.
Quantifiable outcome
- Phase III clinical trials evaluating efficacy in reducing asthma exacerbations and improving lung function
Companies that use Areteia Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
Areteia Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Areteia Therapeutics partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Knopp BiosciencescoreCo-created Areteia Therapeutics alongside Population Health Partners. Knopp Biosciences contributed dexpramipexole as the lead drug candidate for the new company focused on eosinophilic asthma treatment.
- Population Health PartnerscoreCo-created Areteia Therapeutics alongside Knopp Biosciences to develop and commercialize dexpramipexole as an oral treatment for eosinophilic asthma, providing strategic partnership and operational support.
Scale indicators1 record
Recent moves7 records
Expansion highlights4 records
Areteia Therapeutics competitors and assessment
Company assessmentBroad incumbents
- GlaxoSmithKline (GSK): GSK markets Nucala (mepolizumab), an anti-IL-5 biologic approved for severe eosinophilic asthma. It is the most direct commercial competitor to dexpramipexole's target biology and the standard-of-care incumbent Areteia would have needed to displace.
- AstraZeneca: AstraZeneca markets Fasenra (benralizumab), another anti-IL-5 biologic for severe eosinophilic asthma. It is a direct competitor in the eosinophil-targeting asthma space and a benchmark for commercial-stage validation of the underlying mechanism.
- Regeneron Pharmaceuticals: Regeneron co-develops Dupixent (dupilumab) with Sanofi, the market-leading biologic for type 2 inflammatory asthma. It competes in the same severe asthma patient population Areteia targeted.
- Teva Pharmaceutical Industries: Teva is a major respiratory therapeutics player (ProAir, AirDuo, generic ICS/LABA combinations) and operates in the asthma commercial landscape where dexpramipexole would have launched.
Direct peers
- Sanofi: Sanofi co-markets Dupixent (dupilumab) with Regeneron for moderate-to-severe asthma and atopic conditions. As an Areteia investor and a developer of the leading asthma biologic, Sanofi is simultaneously a strategic backer and a primary commercial competitor.
- Knopp Biosciences: Co-founder of Areteia and originator of dexpramipexole. Knopp retained rights to other indications of dexpramipexole (e.g., hypereosinophilic syndrome) and is the upstream R&D parent whose asset powered Areteia's entire pipeline.
Emerging players
- Vertex Pharmaceuticals: Vertex has expanded beyond cystic fibrosis into broader respiratory disease and has been active in clinical-stage inflammation/immunology — a comparable late-stage biotech competitor pursuing novel mechanisms in serious respiratory indications.
- Arcturus Therapeutics: Clinical-stage RNA therapeutics company developing inhaled and respiratory-targeted therapeutics. Comparable as a small-cap, late-stage clinical biotech pursuing differentiated mechanisms in pulmonary disease.
- Upstream Bio: Clinical-stage biotech developing therapeutics for severe asthma and other inflammatory diseases. Comparable as a venture-backed, late-clinical-stage respiratory company targeting type 2 inflammation.
- Pulmatrix: Small clinical-stage respiratory company developing inhaled therapeutics for asthma and COPD. Comparable as a niche respiratory biotech focused on differentiated pulmonary drug delivery.
Market position
Strengths3 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Areteia Therapeutics social profiles
Digital presenceAreteia Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Areteia Therapeutics leadership team
Management profileNumber of profiles
Profiles7 records
Areteia Therapeutics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Areteia Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Areteia Therapeutics
What does Areteia Therapeutics do?
Areteia Therapeutics is developing dexpramipexole, an oral drug candidate designed to lower eosinophil levels in patients with eosinophilic asthma. The lead asset is intended as an oral alternative to injectable biologic therapies and corticosteroids, with the goal of reducing asthma exacerbations and improving lung function. The company was advancing dexpramipexole through Phase III clinical trials as a single-asset clinical-stage biopharmaceutical program.
Is Areteia Therapeutics a public or private company?
Areteia Therapeutics is a private company. It is classified as venture growth investor backed and is currently closed.
When was Areteia Therapeutics founded?
Areteia Therapeutics was founded in 2022. It employs 11 to 50 people.
Where is Areteia Therapeutics based?
Areteia Therapeutics is headquartered in Bernardsville, United States, in the North America region.
Who are Areteia Therapeutics's main competitors?
Broad incumbents on record are GlaxoSmithKline (GSK), AstraZeneca, Regeneron Pharmaceuticals and Teva Pharmaceutical Industries. Direct peers are Sanofi and Knopp Biosciences. Emerging players are Vertex Pharmaceuticals, Arcturus Therapeutics, Upstream Bio and Pulmatrix.
Does Areteia Therapeutics have an API?
No public API is recorded for Areteia Therapeutics.
What industry is Areteia Therapeutics in?
Areteia Therapeutics's product category is Respiratory Therapeutics. Its primary akta.pro industry code is HLAIAAAH, Respiratory & Allergy Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.